Melanoma patients treated with anti-CTLA-4 and anti-PD-1 mAbs who developed immune-related enterocolitis had a better clinical response and OS compared to subjects who developed other adverse events (AEs) [210]. This evidence concerns the gene CTLA4 and melanoma.